Atlanta pediatric research overview center for drug discovery (cdd fibrosarcoma and malignant fibrous histiocytoma) centers research emory + children’s + gt atlanta pediatric research alliance

Emory University has been highly successful in discovering small molecules, which became invaluable in the clinic for treating human diseases fibrosarcoma and malignant fibrous histiocytoma such as HIV/AIDS, HBV and HCV. These successes in drug discovery were possible due to the fibrosarcoma and malignant fibrous histiocytoma innovative work of outstanding academic scientists, as well as strong support from the NIH, CFAR and the University. Using these successes as a stepping stone, the Children’s Center for Drug Discovery serves as an academic hub fibrosarcoma and malignant fibrous histiocytoma of the Emory School of Medicine and Children’s Clinics for executing two highly coordinated and cooperative missions: 1) performing leading-edge basic science research for identifying new disease targets and fibrosarcoma and malignant fibrous histiocytoma 2) translating the newly identified targets to drug design, synthesis, evaluation and selection as potential clinical candidates. The ultimate goals of the Center are the development of fibrosarcoma and malignant fibrous histiocytoma extramurally funded basic research programs and the identification of small fibrosarcoma and malignant fibrous histiocytoma molecule candidates that will contribute to the discovery of new fibrosarcoma and malignant fibrous histiocytoma drugs. The clinical potential of the drugs will be evaluated up fibrosarcoma and malignant fibrous histiocytoma to Phase 2 clinical trials.

Dr. Kim joined Emory’s faculty as a Professor within the Laboratory of Biochemical fibrosarcoma and malignant fibrous histiocytoma Pharmacology in 2013, joining us from the University of Rochester. He guides, oversees, promotes, and develops the Center and facilitates collaborations across the University. Dr. Kim’s 20 years of experience in biochemical and virological research, which has been fully supported by NIH, has been focused on the replication process and cell tropism fibrosarcoma and malignant fibrous histiocytoma of HIV/AIDS and influenza virus. Recently, Dr. Kim has recently initiated enzymological and mechanistic research on WNV fibrosarcoma and malignant fibrous histiocytoma and Dengue RNA polymerases, which will be incorporated into the drug discovery programs of fibrosarcoma and malignant fibrous histiocytoma the center.

Dr. Schinazi serves as the Frances Winship Walters Professor of Pediatrics fibrosarcoma and malignant fibrous histiocytoma and Director of the Laboratory of Biochemical Pharmacology, which houses over 40 scientists specializing in chemistry, virology, molecular biology, biochemistry, pharmacokinetics, and molecular modeling related to the development of drugs to fibrosarcoma and malignant fibrous histiocytoma treat HIV/AIDS, hepatitis B, hepatitis C, herpesviruses, Norovirus, and Dengue. Dr. Schinazi’s proven track record of success in drug discovery and fibrosarcoma and malignant fibrous histiocytoma development, combined with the diversity of scientific expertise within his group, will contribute toward the launch of the Center. Dr, Schinazi serves as the Director of the Scientific Working Group fibrosarcoma and malignant fibrous histiocytoma on Viral Eradication within Emory’s Center for AIDS Research.

Dr. Hurwitz’s expertise in pharmacokinetic (PK) and pharmacodynamic (PD) modeling contributes to antiviral studies conducted in the Laboratory of fibrosarcoma and malignant fibrous histiocytoma Biochemical Pharmacology. He regularly collaborates with the Yerkes Primate Research Center and fibrosarcoma and malignant fibrous histiocytoma the Winship Cancer Institute on studies involving drug development and fibrosarcoma and malignant fibrous histiocytoma dosing for HIV, hepatitis, and cancer.

Dr. Kohler serves as co-Director of the Scientific Working Group on Viral Eradication within fibrosarcoma and malignant fibrous histiocytoma Emory’s Center for AIDS Research. His experience in immunology and animal models is actively engaged fibrosarcoma and malignant fibrous histiocytoma within the Laboratory of Biochemical Pharmacology for drug development studies fibrosarcoma and malignant fibrous histiocytoma and grant proposals involving viral eradication for HIV, hepatitis B, and Dengue.

Dr. Tedbury serves in the Sarafianos Lab and specializes in molecular fibrosarcoma and malignant fibrous histiocytoma biology, virology, retroviruses and RNA viruses. His project emphasis is on the development of efficient reporter fibrosarcoma and malignant fibrous histiocytoma systems for hepatitis B virus (HBV) replication and persitence. This includes identification and characterization of small molecules and host fibrosarcoma and malignant fibrous histiocytoma factors that modulate HBV replication and persistence, as well as interactions between human immundeficiency virus and the fibrosarcoma and malignant fibrous histiocytoma host genome .

RELATED POSTS